首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Single-Dose Phase I Study To Evaluate the Pharmacokinetics of Posaconazole in New Tablet and Capsule Formulations Relative to Oral Suspension
【2h】

Single-Dose Phase I Study To Evaluate the Pharmacokinetics of Posaconazole in New Tablet and Capsule Formulations Relative to Oral Suspension

机译:单剂量I期研究评估泊沙康唑在新片剂和相对于口服混悬剂的胶囊制剂中的药代动力学

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Posaconazole oral suspension, a marketed extended-spectrum triazole with proven efficacy as antifungal treatment and prophylaxis, should be taken with food to maximize absorption. New tablet and capsule formulations have been developed in an attempt to optimize absorption and bioavailability. The aims of this exploratory open-label, partially randomized, 2-part, 4-way, single-dose crossover study in 16 healthy adults were to characterize pharmacokinetics for posaconazole tablet and capsule formulations relative to those for posaconazole oral suspension under fasted and fed conditions and to assess safety and tolerability. Under fasted conditions, posaconazole exposures (area under the curve [AUC]) for the tablet and capsule formulations were similar (mean AUC from time zero to infinity [AUC0–∞], tablet A, 11,700 ng · h/ml [coefficient of variation {CV}, 26%]; tablet B, 11,300 ng · h/ml [CV, 22%]; capsule, 11,000 ng · h/ml [CV, 25%]) and were substantially higher than the exposure for the oral suspension (mean AUC0–∞, 3,420 ng · h/ml [CV, 44%]). Tablets and capsule showed less variability in exposure than the oral suspension. In fed subjects, tablets and capsule resulted in similar AUC values (mean AUC0–∞, tablet A, 11,900 ng · h/ml [23%]; tablet B, 12,400 ng · h/ml [CV, 25%]; capsule, 12,300 ng · h/ml [CV, 28%]) and slightly higher exposure than the oral suspension (mean AUC0–∞, 8,750 [CV, 24%]). Median times to the maximum concentration of drug in plasma were 4 to 5 h (fasted conditions) and 6 to 8 h (fed conditions). Mean half-lives values were similar for all formulations under fed and fasted conditions (23.1 to 29.2 h). Consistent with previous data, exposure for the oral suspension increased 2.5- to 3-fold when it was given with a high-fat meal. Conversely, exposures for tablets and capsule were not markedly affected by food. All formulations of posaconazole at 100 mg were safe and well tolerated.
机译:泊沙康唑口服混悬剂是市售的广谱三唑,具有抗真菌治疗和预防的功效,应与食物一起服用,以最大程度地吸收。为了优化吸收和生物利用度,已经开发了新的片剂和胶囊剂。这项探索性,开放标签,部分随机,2部分,4用药,单剂量交叉研究的目的是表征泊沙康唑片剂和胶囊剂相对于禁食和进食的泊沙康唑口服混悬剂的药代动力学条件并评估安全性和耐受性。在禁食条件下,片剂和胶囊制剂的泊沙康唑暴露量(曲线[AUC]下的面积)相似(零时至无穷大时的平均AUC [AUC0–∞],片剂A的暴露量为11,700 ng·h / ml [变异系数{CV},26%];片剂B,11,300 ng·h / ml [CV,22%];胶囊,11,000 ng·h / ml [CV,25%]),大大高于口服混悬液的暴露量(平均AUC0–∞,3,420 ng·h / ml [CV,44%])。片剂和胶囊剂的暴露变异性小于口服混悬剂。在进食的受试者中,片剂和胶囊的AUC值相似(平均AUC0-∞,片剂A为11,900 ng·h / ml [23%];片剂B为12,400 ng·h / ml [CV,25%]; 12,300 ng·h / ml [CV,28%]),其暴露量略高于口服混悬液(平均AUC0-∞,8,750 [CV,24%])。血浆中药物最大浓度的中位时间为4至5小时(禁食)和6至8小时(进食)。所有配方在进食和禁食条件下(23.1至29.2小时)的平均半衰期值均相似。与以前的数据一致,高脂餐后口服混悬液的暴露量增加了2.5到3倍。相反,片剂和胶囊剂的暴露不受食物的影响明显。 100 mg泊沙康唑的所有制剂均安全且耐受良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号